Repligen (NASDAQ:RGEN) is set to release its earnings data before the market opens on Thursday, February 22nd. Analysts expect Repligen to post earnings of $0.12 per share for the quarter.

Repligen (NASDAQ RGEN) opened at $32.99 on Thursday. The company has a market capitalization of $1,391.91, a price-to-earnings ratio of 55.92, a price-to-earnings-growth ratio of 1.79 and a beta of 0.91. Repligen has a one year low of $29.56 and a one year high of $46.81.

Several brokerages have recently issued reports on RGEN. BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a research note on Wednesday, February 7th. Zacks Investment Research raised Repligen from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. TheStreet lowered Repligen from a “b-” rating to a “c” rating in a research note on Monday, November 13th. Jefferies Group reaffirmed a “hold” rating and set a $40.00 price target on shares of Repligen in a research note on Thursday, October 19th. Finally, JPMorgan Chase & Co. began coverage on Repligen in a research note on Tuesday, December 5th. They set an “overweight” rating and a $42.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. Repligen currently has a consensus rating of “Buy” and an average target price of $44.38.

In other news, CEO Anthony Hunt sold 8,970 shares of the company’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total transaction of $322,471.50. Following the transaction, the chief executive officer now owns 83,613 shares of the company’s stock, valued at $3,005,887.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Howard Benjamin sold 12,729 shares of the company’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $35.34, for a total value of $449,842.86. Following the transaction, the vice president now directly owns 36,554 shares in the company, valued at approximately $1,291,818.36. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Repligen (RGEN) to Release Quarterly Earnings on Thursday” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/02/15/repligen-rgen-to-release-quarterly-earnings-on-thursday.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Earnings History for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.